Vitro Biopharma, Inc.
CIK 793171fmd_180TSQ1N0J6DCS3Q3S4WZ5QCF9Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Nov 01, 2009 to Jul 31, 2026, 41 periods
Latest annual · FY2025
Millions- Total revenues
- 2
- Gross profit
- 2
- Operating income
- (5)
- Net income
- (11)
- Free cash flow
- (3)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 1
- Gross profit
- 0
- Operating income
- (1)
- Net income
- (9)
- Free cash flow
- (2)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -14.5%
- Revenue, 5 yearsFY2014 to FY2025
- +76.6%
- Net income, 5 yearsFY2014 to FY2025
- n/m
Vitro Biopharma, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $2.1 million | $1.9 million | +10.8% | 10-K 2026-02-13 · proof |
| Gross profit | $1.6 million | $1.4 million | +10.1% | 10-K 2026-02-13 · proof |
| Operating income | -$5 million | -$9.2 million | 10-K 2026-02-13 · proof | |
| Net income | -$10.9 million | -$9.9 million | 10-K 2026-02-13 · proof | |
| Cash from operating activities | -$2.5 million | -$3.2 million | 10-K 2026-02-13 · proof | |
| Free cash flow | -$2.5 million | 10-K 2026-02-13 · proof | ||
| Total assets | $4.9 million | $5.2 million | -5.7% | 10-K 2026-02-13 · proof |
| Total liabilities | $21.3 million | $14.2 million | +49.5% | 10-K 2026-02-13 · proof |
| Cash and cash equivalents | $604,183 | $571,360 | +5.7% | 10-K 2026-02-13 · proof |
| Total debt | $9.6 million | $8.2 million | +16.2% | 10-K 2026-02-13 · proof |
- What was Vitro Biopharma, Inc.'s revenue in fiscal 2025?
- Vitro Biopharma, Inc. reported revenue of $2.1 million for fiscal 2025 (the year ended Oct 31, 2025), against $1.9 million the year before (+10.8%). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
- What was Vitro Biopharma, Inc.'s gross profit in fiscal 2025?
- Vitro Biopharma, Inc. reported gross profit of $1.6 million for fiscal 2025 (the year ended Oct 31, 2025), against $1.4 million the year before (+10.1%). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
- What was Vitro Biopharma, Inc.'s operating income in fiscal 2025?
- Vitro Biopharma, Inc. reported operating income of -$5 million for fiscal 2025 (the year ended Oct 31, 2025), against -$9.2 million the year before. Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
- What was Vitro Biopharma, Inc.'s net income in fiscal 2025?
- Vitro Biopharma, Inc. reported net income of -$10.9 million for fiscal 2025 (the year ended Oct 31, 2025), against -$9.9 million the year before. Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
- What was Vitro Biopharma, Inc.'s cash from operating activities in fiscal 2025?
- Vitro Biopharma, Inc. reported cash from operating activities of -$2.5 million for fiscal 2025 (the year ended Oct 31, 2025), against -$3.2 million the year before. Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
- What was Vitro Biopharma, Inc.'s free cash flow in fiscal 2025?
- Vitro Biopharma, Inc. reported free cash flow of -$2.5 million for fiscal 2025 (the year ended Oct 31, 2025). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
- What are Vitro Biopharma, Inc.'s total assets?
- As of Oct 31, 2025, Vitro Biopharma, Inc. reported total assets of $4.9 million, against $5.2 million a year earlier (-5.7%). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
- What are Vitro Biopharma, Inc.'s total liabilities?
- As of Oct 31, 2025, Vitro Biopharma, Inc. reported total liabilities of $21.3 million, against $14.2 million a year earlier (+49.5%). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
- What are Vitro Biopharma, Inc.'s cash and cash equivalents?
- As of Oct 31, 2025, Vitro Biopharma, Inc. reported cash and cash equivalents of $604,183, against $571,360 a year earlier (+5.7%). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
- What is Vitro Biopharma, Inc.'s total debt?
- As of Oct 31, 2025, Vitro Biopharma, Inc. reported total debt of $9.6 million, against $8.2 million a year earlier (+16.2%). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:793171&period_type=annual&limit=5"Information only, not investment advice.